Incyte (ICY) Stock Forecast & Price Target

Compare

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ICY Analyst Ratings

Moderate Buy

7 Buy

10 Hold

1 Sell

Based on 18 analysts giving stock ratings to

Incyte

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ICY Stock 12 Month Forecast

Average Price Target

€81.09

▼(-2.70% Downside)

Based on 18 Wall Street analysts offering 12 month price targets for Incyte in the last 3 months. The average price target is €81.09 with a high forecast of €108.44 and a low forecast of €63.33. The average price target represents a -2.70% change from the last price of €83.34.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"52":"€52","109":"€109","66.25":"€66.3","80.5":"€80.5","94.75":"€94.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":108.44378,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€108.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":81.0899209328,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€81.09</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":63.33116752,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€63.33</span>\n  </div></div>","useHTML":true}}],"tickPositions":[52,66.25,80.5,94.75,109],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,79.74,81.94798307692307,84.15596615384615,86.36394923076922,88.57193230769231,90.77991538461538,92.98789846153846,95.19588153846153,97.40386461538462,99.61184769230769,101.81983076923078,104.02781384615385,106.23579692307692,{"y":108.44378,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,79.74,79.84384007175385,79.94768014350768,80.05152021526153,80.15536028701538,80.25920035876922,80.36304043052307,80.46688050227692,80.57072057403077,80.67456064578461,80.77840071753846,80.88224078929231,80.98608086104615,{"y":81.0899209328,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,79.74,78.47778211692307,77.21556423384615,75.95334635076922,74.69112846769231,73.42891058461538,72.16669270153847,70.90447481846154,69.64225693538461,68.3800390523077,67.11782116923077,65.85560328615385,64.59338540307692,{"y":63.33116752,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":67.96,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.64,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.04,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.5,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.12,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.76,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.1,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.38,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.52,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.82,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.56,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.74,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€108.44

Average Price Target€81.09

Lowest Price Target€63.33

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Peter Lawson

Barclays

€78.08→€87.62

Buy

5.14%

Upside

Reiterated

11/04/25

Barclays Sticks to Its Buy Rating for Incyte (INCY)

Michael Schmidt

Guggenheim

€74.61→€108.44

Buy

30.12%

Upside

Upgraded

11/03/25

Incyte upgraded to Buy from Neutral at GuggenheimIncyte upgraded to Buy from Neutral at Guggenheim

Derek Archila

Wells Fargo

€84.15

Buy

0.97%

Upside

Reiterated

11/03/25

Wells Fargo believes Incyte shares should trade up on INCB0989 abstractWells Fargo believes Incyte shares should trade up on INCB0989 abstract

Marc Frahm

TD Cowen

€87.62

Buy

5.14%

Upside

Reiterated

11/03/25

Incyte (INCY) Receives a Buy from TD Cowen

Evan Seigerman

BMO Capital

€52.05→€65.07

Sell

-21.93%

Downside

Reiterated

11/03/25

BMO Capital Sticks to Its Sell Rating for Incyte (INCY)

Matt Phipps

William Blair

―

Hold

―

Reiterated

11/03/25

Incyte's INCA033989 Shows Promising Initial Results in Myelofibrosis, But Hold Rating Reflects Need for Further Data

Salim Syed

Mizuho Securities

€78.08

Hold

-6.31%

Downside

Reiterated

11/03/25

Mizuho says Incyte myelofibrosis efficacy data look 'promising,' but still earlyMizuho says Incyte myelofibrosis efficacy data look 'promising,' but still early

Unknown Analyst

Evercore ISI

Not Ranked

Evercore ISI

€63.33

Hold

-24.01%

Downside

Reiterated

11/03/25

Evercore ISI Reaffirms Their Hold Rating on Incyte (INCY)

Srikripa Devarakonda

Truist Financial

€68.54→€80.68

Hold

-3.19%

Downside

Assigned

10/29/25

Incyte (INCY) Receives a Hold from Truist Financial

Brian Abrahams

RBC Capital

€70.27→€72.87

Hold

-12.56%

Downside

Reiterated

10/28/25

Incyte (INCY) Gets a Hold from RBC Capital

Tazeen Ahmad

Bank of America Securities

€90.23→€94.56

Buy

13.47%

Upside

Reiterated

10/28/25

Incyte's Strong Financial Performance and Strategic Catalysts Drive Buy Rating

Jessica Fye

J.P. Morgan

―

Hold

―

Reiterated

10/20/25

Incyte's Clinical Developments Show Promise Amidst Competitive Challenges and Uncertain Revenue Potential

Jay Olson

Oppenheimer

€71.14

Hold

-14.64%

Downside

Reiterated

10/20/25

Oppenheimer Reaffirms Their Hold Rating on Incyte (INCY)

Stephen Willey

Stifel Nicolaus

€99.77

Buy

19.71%

Upside

Reiterated

10/20/25

Stifel Nicolaus Reaffirms Their Buy Rating on Incyte (INCY)

Judah Frommer

Morgan Stanley

€68.54

Hold

-17.76%

Downside

Reiterated

10/20/25

Cautious Optimism for Incyte's Early-Stage Cancer Therapies: Hold Rating Pending Further Data

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Peter Lawson

Barclays

€78.08→€87.62

Buy

5.14%

Upside

Reiterated

11/04/25

Barclays Sticks to Its Buy Rating for Incyte (INCY)

Michael Schmidt

Guggenheim

€74.61→€108.44

Buy

30.12%

Upside

Upgraded

11/03/25

Incyte upgraded to Buy from Neutral at GuggenheimIncyte upgraded to Buy from Neutral at Guggenheim

Derek Archila

Wells Fargo

€84.15

Buy

0.97%

Upside

Reiterated

11/03/25

Wells Fargo believes Incyte shares should trade up on INCB0989 abstractWells Fargo believes Incyte shares should trade up on INCB0989 abstract

Marc Frahm

TD Cowen

€87.62

Buy

5.14%

Upside

Reiterated

11/03/25

Incyte (INCY) Receives a Buy from TD Cowen

Evan Seigerman

BMO Capital

€52.05→€65.07

Sell

-21.93%

Downside

Reiterated

11/03/25

BMO Capital Sticks to Its Sell Rating for Incyte (INCY)

Matt Phipps

William Blair

―

Hold

―

Reiterated

11/03/25

Incyte's INCA033989 Shows Promising Initial Results in Myelofibrosis, But Hold Rating Reflects Need for Further Data

Salim Syed

Mizuho Securities

€78.08

Hold

-6.31%

Downside

Reiterated

11/03/25

Mizuho says Incyte myelofibrosis efficacy data look 'promising,' but still earlyMizuho says Incyte myelofibrosis efficacy data look 'promising,' but still early

Unknown Analyst

Evercore ISI

Not Ranked

Evercore ISI

€63.33

Hold

-24.01%

Downside

Reiterated

11/03/25

Evercore ISI Reaffirms Their Hold Rating on Incyte (INCY)

Srikripa Devarakonda

Truist Financial

€68.54→€80.68

Hold

-3.19%

Downside

Assigned

10/29/25

Incyte (INCY) Receives a Hold from Truist Financial

Brian Abrahams

RBC Capital

€70.27→€72.87

Hold

-12.56%

Downside

Reiterated

10/28/25

Incyte (INCY) Gets a Hold from RBC Capital

Tazeen Ahmad

Bank of America Securities

€90.23→€94.56

Buy

13.47%

Upside

Reiterated

10/28/25

Incyte's Strong Financial Performance and Strategic Catalysts Drive Buy Rating

Jessica Fye

J.P. Morgan

―

Hold

―

Reiterated

10/20/25

Incyte's Clinical Developments Show Promise Amidst Competitive Challenges and Uncertain Revenue Potential

Jay Olson

Oppenheimer

€71.14

Hold

-14.64%

Downside

Reiterated

10/20/25

Oppenheimer Reaffirms Their Hold Rating on Incyte (INCY)

Stephen Willey

Stifel Nicolaus

€99.77

Buy

19.71%

Upside

Reiterated

10/20/25

Stifel Nicolaus Reaffirms Their Buy Rating on Incyte (INCY)

Judah Frommer

Morgan Stanley

€68.54

Hold

-17.76%

Downside

Reiterated

10/20/25

Cautious Optimism for Incyte's Early-Stage Cancer Therapies: Hold Rating Pending Further Data

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Incyte

1 Month

xxx

Success Rate

10/15 ratings generated profit

Average Return

-0.68%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of -0.68% per trade.

3 Months

xxx

Success Rate

11/18 ratings generated profit

Average Return

+3.59%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 61.11% of your transactions generating a profit, with an average return of +3.59% per trade.

1 Year

David LebowitzCiti

Success Rate

15/15 ratings generated profit

Average Return

+25.14%

reiterated a buy rating 3 months ago

Copying David Lebowitz's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +25.14% per trade.

2 Years

xxx

Success Rate

15/15 ratings generated profit

Average Return

+34.93%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +34.93% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ICY Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ICY has received 21 Buy Ratings, 21 Hold Ratings, and 1 Sell Ratings. ICY average Analyst price target in the past 3 months is 81.09.

Each month's total comprises the sum of three months' worth of ratings.

ICY Financial Forecast

ICY Earnings Forecast

Next quarter’s earnings estimate for ICY is €1.66 with a range of €1.45 to €1.96. The previous quarter’s EPS was €1.96. ICY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year ICY has Preformed in-line its overall industry.

ICY Sales Forecast

Next quarter’s sales forecast for ICY is €1.17B with a range of €1.14B to €1.24B. The previous quarter’s sales results were €1.19B. ICY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year ICY has Preformed in-line its overall industry.

ICY Stock Forecast FAQ

What is DE:ICY’s average 12-month price target, according to analysts?

Based on analyst ratings, Incyte Corp’s 12-month average price target is 81.09.

What is DE:ICY’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for DE:ICY, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Incyte Corp a Buy, Sell or Hold?

Incyte Corp has a consensus rating of Moderate Buy, which is based on 7 buy ratings, 10 hold ratings and 1 sell ratings.

What is Incyte Corp’s share price target?

The average share price target for Incyte Corp is 81.09. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €108.44 ,and the lowest forecast is €63.33. The average share price target represents -2.70% Decrease from the current price of €83.34.

What do analysts say about Incyte Corp?

Incyte Corp’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of Incyte Corp?

To buy shares of DE:ICY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Incyte (ICY) Stock Forecast & Price Target

ICY Analyst Ratings

ICY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Incyte

ICY Analyst Recommendation Trends

ICY Financial Forecast

ICY Earnings Forecast

ICY Sales Forecast

ICY Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts